{"id":10444,"date":"2018-05-17T09:53:31","date_gmt":"2018-05-17T13:53:31","guid":{"rendered":"https:\/\/medicarereport.org\/?p=10444"},"modified":"2018-05-17T09:53:31","modified_gmt":"2018-05-17T13:53:31","slug":"in-a-first-fda-approves-drug-meant-to-mitigate-symptoms-of-opioid-withdrawal","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=10444","title":{"rendered":"In a first, FDA approves drug meant to mitigate symptoms of opioid withdrawal"},"content":{"rendered":"<p>(By Lev Facher for ST<em>A<\/em>T)<\/p>\n<p class=\"big-cap-wrap danger-zone\"><span class=\"big-cap\">WASHINGTON \u2014 The Food and Drug Administration on Wednesday approved for the first time a drug meant to mitigate the symptoms of opioid withdrawal \u2014 rather than an underlying dependency \u2014 giving American physicians a new tool to help patients begin treatment. <a href=\"https:\/\/www.statnews.com\/2018\/05\/16\/fda-approves-lofexidine-opioid-withdrawal\/?_hsenc=p2ANqtz-8JY2XL04bq2S1AjACRPPjlTsy0IQIzKtyGpj8uarWwOwpjUZ5hCPF0u_kMBfT6_G4tCtRyWzn2hd_91uejnVh9OGNLpQ&amp;_hsmi=62998288\">Continue reading article here&#8230;<\/a><\/span><\/p>\n<p class=\"big-cap-wrap danger-zone\"><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p class=\"big-cap-wrap danger-zone\">\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Lev Facher for STAT) WASHINGTON \u2014 The Food and Drug Administration on Wednesday approved for the first time a<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17,31,15],"tags":[],"class_list":["post-10444","post","type-post","status-publish","format-standard","hentry","category-emerging-health-issues","category-fda","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/10444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10444"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/10444\/revisions"}],"predecessor-version":[{"id":10445,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/10444\/revisions\/10445"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}